Novartis (NVS) Competitors

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.

Is NVO or NVS more profitable?

Novartis has a net margin of 35.96% compared to Novo Nordisk A/S's net margin of 35.03%. Novo Nordisk A/S's return on equity of 86.32% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.03%	86.32%	27.42%
Novartis	35.96%	34.80%	15.13%

Which has more risk & volatility, NVO or NVS?

Novo Nordisk A/S has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of NVO or NVS?

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer NVO or NVS?

Novartis received 105 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. However, 61.81% of users gave Novo Nordisk A/S an outperform vote while only 60.94% of users gave Novartis an outperform vote.

Company	Underperform	Outperform
Novo Nordisk A/S	Outperform Votes 424 61.81%	Underperform Votes 262 38.19%
Novartis	Outperform Votes 529 60.94%	Underperform Votes 339 39.06%

Do analysts rate NVO or NVS?

Novo Nordisk A/S presently has a consensus price target of $150.40, indicating a potential upside of 76.94%. Novartis has a consensus price target of $121.50, indicating a potential upside of 25.12%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Novartis	2 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.78

Is NVO or NVS a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.72 per share and has a dividend yield of 0.8%. Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.5%. Novo Nordisk A/S pays out 23.3% of its earnings in the form of a dividend. Novartis pays out 28.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Which has preferable valuation & earnings, NVO or NVS?

Novartis has lower revenue, but higher earnings than Novo Nordisk A/S. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$270.58B	1.41	$12.15B	$3.09	27.51
Novartis	$49.94B	3.97	$14.85B	$8.61	11.28

Does the media prefer NVO or NVS?

In the previous week, Novo Nordisk A/S had 35 more articles in the media than Novartis. MarketBeat recorded 50 mentions for Novo Nordisk A/S and 15 mentions for Novartis. Novartis' average media sentiment score of 0.83 beat Novo Nordisk A/S's score of 0.27 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	13 Very Positive mention(s)	6 Positive mention(s)	18 Neutral mention(s)	12 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novartis	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Novartis on 12 of the 21 factors compared between the two stocks.